In a development in the pharmaceutical industry, directors of Marion Biotech, Sachin Jain and Jaya Jain, find themselves embroiled in legal battles following a series of controversial events. The Indian Drugs Authorities, alongside other government departments, have initiated three separate cases against the directors, citing various allegations, representative of Marion Biotech told Daryo.
Further complicating matters is the recent filing of cases against the Marion Biotech directors by Indian authorities in January 2024.
"Recently in Jan-2024 Indian Drugs Authorities and other departments of Government of India have filed three different cases against directors of Marion Biotech Sachin Jain & Jaya Jain. Next hearing on 22nd March 2024 but they both are absconding,"- representative stated.
Adding to the complexity of the situation is the revelation of Sachin Jain's extensive network of business interests, including numerous shell companies across Mauritius, Singapore, and Dubai. These entities, allegedly used for exporting purposes, raise suspicions regarding the transparency and legality of Marion Biotech's operations.
Case overview
Key individuals in the legal proceedings include S.R.P. and S.K., holding significant positions in Quramax Medical and the State Center for Expertise and Standardization of Medicines, Medical Products, and Medical Equipment, respectively. The case involves a total of 21 individuals, with 16 men and 5 women among the defendants. Presently, 7 defendants are detained, 12 have been advised to exhibit good conduct, and 2 are subject to precautionary measures involving bail.
The accused face a range of charges outlined in the Criminal Code. These charges encompass allegations of involvement in pharmaceutical misconduct, negligence, and potentially manslaughter. The seriousness of the accusations is underscored by the tragic outcome of their actions: the deaths of 65 young children who consumed the "Dok-1 Max" syrup.
The Uzbekistan government has implemented stringent measures, recalling Dok-1 Max tablets and syrups from all pharmacies nationwide following the discovery of the harmful substance. This legal action follows a tragic incident in Gambia, where at least 70 children lost their lives due to cough and cold syrups associated with Maiden Pharmaceuticals, a company based in New Delhi. Both the Indian government and Maiden Pharmaceuticals have refuted any wrongdoing.
In the court session held on January 10, it was emphasized that a fresh criminal case had been merged with the existing charges, amalgamating them into a unified case. The prosecutor, outlining the allegations, mentioned that the death count attributed to the syrup has now risen to 68, marking a departure from the figures initially reported by the Supreme Court.
Comments (0)